Magrolimab plus azacitidine results in promising activity in higher-risk MDS patients
byH. Lee Moffitt Cancer Center & Research InstituteHemoglobin changes from baseline over time on treatment with magrolimab + azacitidine in patients with HR-MDS (N = 95). Data shown are medi
Updated on: December 28,2023
9
Magrolimab plus azacitidine results in promising activity in higher-risk MDS patients
byH. Lee Moffitt Cancer Center & Research InstituteHemoglobin changes from baseline over time on treatment with magrolimab + azacitidine in patients with HR-MDS (N = 95). Data shown are medi
Updated on:December 28,2023
9
